Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Summary

The investigator's want to find out if treatment with ibrutinib, rituximab, and lenalidomide are safe and better than the usual approach in patients with recurrent or refractory central nervous system lymphoma.

Timeline

Start

2019-01-22

Primary completion

2026-01-26

Completion

2026-01-26

Publications

• Schaff LR, Piotrowski AF, Pentsova E, Gavrilovic IT, Lin A, Kaley TJ, Wongchai V, Emadi-Paramkouhi L, Madzsar J, Quinn L, Gonzalez A, Breakey L, Tang SS, Mendez JS, Malani R, Nolan C, Hatzoglou V, Young RJ, DeAngelis LM, Reiner AS, Panageas KS, Francis JH, Mellinghoff IK, Grommes C. Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma. Neuro Oncol. 2025 Sep 17;27(8):2107-2116. doi: 10.1093/neuonc/noaf104.

Drugs

Indications